TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07015905: A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2000 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,173,128

Rescue Site Savings

+$7,354,464

Unlock Full NCT07015905 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07015905 Rescue Dossier →